June 9, 2009
Neal Meropol, MD, has been recruited as Associate Director for Clinical Research at the Case Comprehensive Cancer Center. Dr. Meropol has an outstanding track record as a clinical and translational investigator and will assume a prominent role at our cancer center. He received his MD from Vanderbilt, was a resident at University Hospitals, Case Western Reserve University School of Medicine, and a fellow at University of Pennsylvania. He began his academic career at Roswell Park Cancer Institute where he was on faculty with Dr. Derek Raghavan, and moved to Fox Chase Cancer Center in 1998 where he pursued his interests in GI malignancies, developmental therapeutics, and patient decision making. Dr. Meropol recently completed a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.
Dr. Meropol has a national reputation for his contributions in GI malignancies including evaluation of new agents, predictors of response and outcome, and assessment of the economic impact of care. He is also well-recognized for his work in patient decision making and doctor-patient communication, in particular with regard to early phase clinical trials. Through his national leadership roles as Chair of the Eastern Cooperative Oncology Group Developmental Therapeutics committee, Chair of the NCI Colon Cancer Task Force, and Chair-elect of the ASCO Cancer Research Committee, he will be able to facilitate the introduction of local discoveries and ideas to the national stage. He has been honored with a number of awards including teaching awards and honorary lectureships.
At the Case CCC, Dr. Meropol will oversee clinical and translational research, working closely with Drs. Afshin Dowlati and John Sweetenham, who remain as Deputy Associate Directors for Clinical Research at their respective institutions. He will also work with Dr. Sweetenham in his role as Director for Clinical Trials to improve efficiencies of protocol development, implementation and monitoring. He and Dr. Sandy Markowitz will work together on the GI Spore initiative. Dr. Meropol will encourage investigator-initiated clinical trials across the Cancer Center, encourage translational and laboratory correlative studies, and provide a focal point for transdisciplinary research assessing outcomes and population impact of innovative therapies and predictors of treatment response.
Dr. Meropol will be a member of the Case CCC Senior Leaders group, helping to shape the priorities and developing strategies for allocation of the considerable resources available to the center. He will also have a position in the Department of Medicine at UHCMC, as Section Chief for Medical Oncology and within the Ireland Cancer Center as Associate Director for Clinical Programs.
Dr. Meropol will be on campus as of early July. He will attend our upcoming Cancer Center Retreat, where he will deliver introductory comments. Please join us in welcoming Dr. Meropol to the Cancer Center. If you would like to contact him prior to his arrival, please use his email: email@example.com.